# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001193125-25-273228
Filing Date
2025-11-10
Accepted
2025-11-10 07:05:25
Documents
14
Period of Report
2025-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | olma-20251110.htm iXBRL | 8-K | 45420
2 | EX-99.1 | olma-ex99_1.htm | EX-99.1 | 39416
3 | GRAPHIC | img39466132_0.jpg | GRAPHIC | 512288
4 | GRAPHIC | img39466132_1.jpg | GRAPHIC | 105861
5 | GRAPHIC | img39466132_2.jpg | GRAPHIC | 482878
| Complete submission text file | 0001193125-25-273228.txt |  | 1714864

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | olma-20251110.xsd | EX-101.SCH | 24998
16 | EXTRACTED XBRL INSTANCE DOCUMENT | olma-20251110_htm.xml | XML | 4749

Mailing Address 780 BRANNAN STREET SAN FRANCISCO CA 94103
Business Address 780 BRANNAN STREET SAN FRANCISCO CA 94103 (415) 651-3316
Olema Pharmaceuticals, Inc. (Filer) CIK: 0001750284 (see all company filings)

EIN.: 300409740 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39712 | Film No.: 251464286
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)